Hidden killers: Human fungal infections

Science Translational Medicine

Volumn 4, Issue 165, 2012, Pages

  Brown, Gordon D ^a   Denning, David W ^b   Gow, Neil A R ^a   Levitz, Stuart M ^c   Netea, Mihai G ^d   White, Theodore C ^e  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; ECHINOCANDIN; FUNGUS VACCINE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; LECTIN RECEPTOR; METHOTREXATE; POSACONAZOLE; STAT1 PROTEIN; STAT3 PROTEIN; TOLL LIKE RECEPTOR; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIFUNGAL RESISTANCE; ASPERGILLOSIS; BLOOD CULTURE; CANDIDIASIS; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DERMATOPHYTE; DRUG MEGADOSE; FUNGUS IDENTIFICATION; HELPER CELL; HOST RESISTANCE; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; LUNG ASPERGILLOSIS; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; POINT OF CARE TESTING; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC MYCOSIS;

HUMANS; MYCOSES;

EID: 84871502341     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004404     Document Type: Review

References (88)

1. M. C. Fisher, D. A. Henk, C. J. Briggs, J. S. Brownstein, L. C. Madoff, S. L. McCraw, S. J. Gurr, Emerging fungal threats to animal, plant and ecosystem health. Nature 484, 186-194 (2012).
2. B. Havlickova, V. A. Czaika, M. Friedrich, Epidemiological trends in skin mycoses worldwide. Mycoses 51 (Suppl. 4), 2-15 (2008).
3. J. Thomas, G. A. Jacobson, C. K. Narkowicz, G. M. Peterson, H. Burnet, C. Sharpe, Toenail onychomycosis: An important global disease burden. J. Clin. Pharm. Ther. 35, 497-519 (2010).
4. J. D. Sobel, Vulvovaginal candidosis. Lancet 369, 1961-1971 (2007).
5. M. Saccente, in Clinical Mycology, E. J. Anaissie, M. R. McGinnia, M. A. Pfaller, Eds. (Churchill Livingstone, London, UK, 2009), pp. 417-429.
6. World Health Organization, Tuberculosis; http://www.who.int/mediacentre/ factsheets/fs104/en/.
7. World Health Organization, Malaria; http://www.who.int/mediacentre/ factsheets/fs094/en/.
8. B. J. Park, K. A. Wannemuehler, B. J. Marston, N. Govender, P. G. Pappas, T. M. Chiller, Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23, 525-530 (2009).
9. J. W. Kronstad, R. Attarian, B. Cadieux, J. Choi, C. A. D'Souza, E. J. Griffiths, J. M. Geddes, G. Hu, W. H. Jung, M. Kretschmer, S. Saikia, J. Wang, Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat. Rev. Microbiol. 9, 193-203 (2011).
10. E. J. Byrnes III, W. Li, Y. Lewit, H. Ma, K. Voelz, P. Ren, D. A. Carter, V. Chaturvedi, R. J. Bildfell, R. C. May, J. Heitman, Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6, e1000850 (2010).
11. J. R. Harris, S. R. Lockhart, E. Debess, N. Marsden-Haug, M. Goldoft, R. Wohrle, S. Lee, C. Smelser, B. Park, T. Chiller, Cryptococcus gattii in the United States: Clinical aspects of infection with an emerging pathogen. Clin. Infect. Dis. 53, 1188-1195 (2011).
12. J. A. Fraser, S. S. Giles, E. C. Wenink, S. G. Geunes-Boyer, J. R. Wright, S. Diezmann, A. Allen, J. E. Stajich, F. S. Dietrich, J. R. Perfect, J. Heitman, Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437, 1360-1364 (2005).
13. H. Wisplinghoff, T. Bischoff, S. M. Tallent, H. Seifert, R. P. Wenzel, M. B. Edmond, Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39, 309-317 (2004).
14. M. A. Pfaller, D. J. Diekema, Epidemiology of invasive candidiasis: A persistent public health problem. Clin. Microbiol. Rev. 20, 133-163 (2007).
15. B. Almirante, D. Rodríguez, B. J. Park, M. Cuenca-Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, P. Saballs, S. K. Fridkin, J. Morgan, J. L. Rodriguez-Tudela, D. W. Warnock, A. Pahissa; Barcelona Candidemia Project Study Group, Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-based surveillance, barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43, 1829-1835 (2005).
16. M. C. Arendrup, K. Fuursted, B. Gahrn-Hansen, I. M. Jensen, J. D. Knudsen, B. Lundgren, H. C. Schønheyder, M. Tvede, Seminational surveillance of fungemia in Denmark: Notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43, 4434-4440 (2005).
17. M. C. Arendrup, K. Fuursted, B. Gahrn-Hansen, H. C. Schønheyder, J. D. Knudsen, I. M. Jensen, B. Bruun, J. J. Christensen, H. K. Johansen, Semi-national surveillance of fungaemia in Denmark 2004-2006: Increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14, 487-494 (2008).
18. L. R. Asmundsdóttir, H. Erlendsdóttir, G. Haraldsson, H. Guo, J. Xu, M. Gottfredsson, Molecular epidemiology of candidemia: Evidence of clusters of smoldering nosocomial infections. Clin. Infect. Dis. 47, e17-e24 (2008).
19. D. J. Diekema, S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, M. A. Pfaller, Epidemiology of candidemia: 3-Year results from the emerging infections and the epidemiology of Iowa organisms study. J. Clin. Microbiol. 40, 1298-1302 (2002).
20. R. A. Hajjeh, A. N. Sofair, L. H. Harrison, G. M. Lyon, B. A. Arthington-Skaggs, S. A. Mirza, M. Phelan, J. Morgan,W. Lee-Yang,M. A. Ciblak, L. E. Benjamin, L. T. Sanza, S. Huie, S. F. Yeo,M. E. Brandt, D. W. Warnock, Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42, 1519-1527 (2004).
21. P. Sandven, L. Bevanger, A. Digranes, H. H. Haukland, T. Mannsåker, P. Gaustad; Norwegian Yeast Study Group, Candidemia in Norway (1991 to 2003): Results from a nationwide study. J. Clin. Microbiol. 44, 1977-1981 (2006).
22. G. St-Germain, M. Laverdière, R. Pelletier, P. René, A. M. Bourgault, C. Lemieux, M. Libman, Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can. J. Infect. Dis. Med. Microbiol. 19, 55-62 (2008).
23. F. C. Odds, M. F. Hanson, A. D. Davidson, M. D. Jacobsen, P. Wright, J. A. Whyte, N. A. Gow, B. L. Jones, One year prospective survey of Candida bloodstream infections in Scotland. J. Med. Microbiol. 56, 1066-1075 (2007).
24. U.S. & World Population Clocks; http://www.census.gov/main/www/ popclock.html.
25. J. Morgan, Global trends in candidemia: Review of reports from 1995-2005. Curr. Infect. Dis. Rep. 7, 429-439 (2005).
26. W. W. Hope, T. J. Walsh, D. W. Denning, The invasive and saprophytic syndromes due to Aspergillus spp. Med. Mycol. 43 (Suppl. 1), S207-S238 (2005).
27. J. Guinea, M. Torres-Narbona, P. Gijón, P. Muñoz, F. Pozo, T. Peláez, J. de Miguel, E. Bouza, Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome. Clin. Microbiol. Infect. 16, 870-877 (2010).
28. C. Garcia-Vidal, A. Upton, K. A. Kirby, K. A. Marr, Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: Biological risk factors for infection according to time after transplantation. Clin. Infect. Dis. 47, 1041-1050 (2008).
29. D. W. Denning, A. Pleuvry, D. C. Cole, Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med. Mycol., 10.3109/13693786.2012.738312 (2012).
30. H. S. Nam, K. Jeon, S. W. Um, G. Y. Suh, M. P. Chung, H. Kim, O. J. Kwon, W. J. Koh, Clinical characteristics and treatment outcomes of chronic necrotizing pulmonary aspergillosis: A review of 43 cases. Int. J. Infect. Dis. 14, e479-e482 (2010).
31. D. W. Denning, A. Pleuvry, D. C. Cole, Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull. World Health Organ. 89, 864-872 (2011).
32. A. Fairs, J. Agbetile, B. Hargadon, M. Bourne, W. R. Monteiro, C. E. Brightling, P. Bradding, R. H. Green, K. Mutalithas, D. Desai, I. D. Pavord, A. J. Wardlaw, C. H. Pashley, IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am. J. Respir. Crit. Care Med. 182, 1362-1368 (2010).
33. D. W. Denning, B. R. O'Driscoll, C. M. Hogaboam, P. Bowyer, R. M. Niven, The link between fungi and severe asthma: A summary of the evidence. Eur. Respir. J. 27, 615-626 (2006).
34. D. Menzies, L. Holmes, G. McCumesky, C. Prys-Picard, R. Niven, Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy 66, 679-685 (2011).
35. T. Eaton, J. Garrett, D. Milne, A. Frankel, A. U. Wells, Allergic bronchopulmonary aspergillosis in the asthma clinic. A prospective evaluation of CT in the diagnostic algorithm. Chest 118, 66-72 (2000).
36. A. P. Knutsen, R. G. Slavin, Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin. Dev. Immunol. 2011, 843763 (2011).
37. E. M. Carmona, A. H. Limper, Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther. Adv. Respir. Dis. 5, 41-59 (2011).
38. A. Morris, K. Wei, K. Afshar, L. Huang, Epidemiology and clinical significance of pneumocystis colonization. J. Infect. Dis. 197, 10-17 (2008).
39. P. D. Walzer, H. E. Evans, A. J. Copas, S. G. Edwards, A. D. Grant, R. F. Miller, Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin. Infect. Dis. 46, 625-633 (2008).
40. D. T. Fisk, S. Meshnick, P. H. Kazanjian, Pneumocystis carinii pneumonia in patients in the developing world who have acquired immunodeficiency syndrome. Clin. Infect. Dis. 36, 70-78 (2003).
41. L. C. D'Avignon, C. M. Schofield, D. R. Hospenthal, Pneumocystis pneumonia. Semin. Respir. Crit. Care Med. 29, 132-140 (2008).
42. H. I. Hall, R. Song, P. Rhodes, J. Prejean, Q. An, L. M. Lee, J. Karon, R. Brookmeyer, E. H. Kaplan, M. T. McKenna, R. S. Janssen; HIV Incidence Surveillance Group, Estimation of HIV incidence in the United States. JAMA 300, 520-529 (2008).
43. Current Epidemiology of Pneumocystis Pneumonia; http://www.medscape.com/ viewarticle/490562-6.
44. Avert, HIV and AIDS statistics from around the world; http://www.avert.org/aids-statistics.htm.
45. A. Morris, J. D. Lundgren, H.Masur, P. D. Walzer, D. L. Hanson, T. Frederick, L. Huang, C. B. Beard, J. E. Kaplan, Current epidemiology of Pneumocystis pneumonia. Emerg. Infect. Dis. 10, 1713-1720 (2004).
46. A. Morris, K. A. Norris, Colonization by Pneumocystis jirovecii and its role in disease. Clin. Microbiol. Rev. 25, 297-317 (2012).
47. http://www.who.int/topics/global-burden-of-disease/en/
48. M. Srinivasan, Fungal keratitis. Curr. Opin. Ophthalmol. 15, 321-327 (2004).
49. G. D. Brown, How fungi have shaped our understanding of mammalian immunology. Cell Host Microbe 7, 9-11 (2010).
50. G. D. Brown, M. G. Netea, Exciting developments in the immunology of fungal infections. Cell Host Microbe 11, 422-424 (2012).
51. M. G. Netea, L. Maródi, Innate immune mechanisms for recognition and uptake of Candida species. Trends Immunol. 31, 346-353 (2010).
52. J. D. Milner, J. M. Brenchley, A. Laurence, A. F. Freeman, B. J. Hill, K. M. Elias, Y. Kanno, C. Spalding, H. Z. Elloumi, M. L. Paulson, J. Davis, A. Hsu, A. I. Asher, J. O'Shea, S. M. Holland, W. E. Paul, D. C. Douek, Impaired TH17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452, 773-776 (2008).
53. L. Liu, S. Okada, X. F. Kong, A. Y. Kreins, S. Cypowyj, A. Abhyankar, J. Toubiana, Y. Itan, M. Audry, P. Nitschke, C. Masson, B. Toth, J. Flatot, M. Migaud, M. Chrabieh, T. Kochetkov, A. Bolze, A. Borghesi, A. Toulon, J. Hiller, S. Eyerich, K. Eyerich, V. Gulácsy, L. Chernyshova, V. Chernyshov, A. Bondarenko, R. M. Grimaldo, L. Blancas-Galicia, I. M. Beas, J. Roesler, K. Magdorf, D. Engelhard, C. Thumerelle, P. R. Burgel, M. Hoernes, B. Drexel, R. Seger, T. Kusuma, A. F. Jansson, J. Sawalle-Belohradsky, B. Belohradsky, E. Jouanguy, J. Bustamante, M. Bué, N. Karin, G. Wildbaum, C. Bodemer, O. Lortholary, A. Fischer, S. Blanche, S. Al-Muhsen, J. Reichenbach, M. Kobayashi, F. E. Rosales, C. T. Lozano, S. S. Kilic, M. Oleastro, A. Etzioni, C. Traidl-Hoffmann, E. D. Renner, L. Abel, C. Picard, L. Maródi, S. Boisson-Dupuis, A. Puel, J. L. Casanova, Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 208, 1635-1648 (2011).
54. F. L. van de Veerdonk, T. S. Plantinga, A. Hoischen, S. P. Smeekens, L. A. Joosten, C. Gilissen, P. Arts, D. C. Rosentul, A. J. Carmichael, C. A. Smits-van der Graaf, B. J. Kullberg, J.W. van derMeer, D. Lilic, J. A. Veltman, M. G. Netea, STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365, 54-61 (2011).
55. I. D. Iliev, V. A. Funari, K. D. Taylor, Q. Nguyen, C. N. Reyes, S. P. Strom, J. Brown, C. A. Becker, P. R. Fleshner, M. Dubinsky, J. I. Rotter, H. L. Wang, D. P. McGovern, G. D. Brown, D. M. Underhill, Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science 336, 1314-1317 (2012).
56. J. N. Jarvis, A. Percival, S. Bauman, J. Pelfrey, G.Meintjes, G. N. Williams, N. Longley, T. S. Harrison, T. R. Kozel, Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 53, 1019-1023 (2011).
57. K. A. Marr, S. A. Balajee, L. McLaughlin, M. Tabouret, C. Bentsen, T. J. Walsh, Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: Variables that affect performance. J. Infect. Dis. 190, 641-649 (2004).
58. C. J. Clancy, R. A. Jaber, H. L. Leather, J. R. Wingard, B. Staley, L. J. Wheat, C. L. Cline, K. H. Rand, D. Schain, M. Baz, M. H. Nguyen, Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J. Clin. Microbiol. 45, 1759-1765 (2007).
59. http://www.bccresearch.com/report/PHM029C.html
60. L. Ostrosky-Zeichner, A. Casadevall, J. N. Galgiani, F. C. Odds, J. H. Rex, An insight into the antifungal pipeline: Selected new molecules and beyond. Nat. Rev. Drug Discov. 9, 719-727 (2010).
61. D. W. Denning, W. W. Hope, Therapy for fungal diseases: Opportunities and priorities. Trends Microbiol. 18, 195-204 (2010).
62. P. E. Verweij, E. Snelders, G. H. Kema, E. Mellado, W. J. Melchers, Azole resistance in Aspergillus fumigatus: A side-effect of environmental fungicide use? Lancet Infect. Dis. 9, 789-795 (2009).
63. A. Jackson, M. C. Hosseinipour, Management of cryptococcal meningitis in sub-Saharan Africa. Curr. HIV/AIDS Rep. 7, 134-142 (2010).
64. D. W. Denning, K. Riniotis, R. Dobrashian, H. Sambatakou, Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature change, and review. Clin. Infect. Dis. 37 (Suppl. 3), S265-S280 (2003).
65. D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, M. Diaz, A. Rendon, G. A. Cloud, D. A. Stevens, Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann. Intern. Med. 124, 305-310 (1996).
66. L. Chishimba, R. M. Niven, J. Cooley, D. W. Denning, Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J. Asthma 49, 423-433 (2012).
67. D. W. Denning, B. R. O'Driscoll, G. Powell, F. Chew, G. T. Atherton, A. Vyas, J. Miles, J. Morris, R. M. Niven, Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am. J. Respir. Crit. Care Med. 179, 11-18 (2009).
68. G. A. Eschenauer, S. W. Lam, P. L. Carver, Antifungal prophylaxis in liver transplant recipients. Liver Transpl. 15, 842-858 (2009).
69. A. Cassone, Fungal vaccines: Real progress from real challenges. Lancet Infect. Dis. 8, 114-124 (2008).
70. B. Spellberg, Vaccines for invasive fungal infections. F1000 Med. Rep. 3, 13 (2011).
71. S. M. Levitz, D. T. Golenbock, Beyond empiricism: Informing vaccine development through innate immunity research. Cell 148, 1284-1292 (2012).
72. + T cells: Implications for vaccine development in immune-deficient hosts. J. Exp. Med. 197, 1405-1416 (2003).
73. P. G. Pappas, B. Bustamante, E. Ticona, R. J. Hamill, P. C. Johnson, A. Reboli, J. Aberg, R. Hasbun, H. H. Hsu, Recombinant interferon-γ1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J. Infect. Dis. 189, 2185-2191 (2004).
74. F. C. Odds, A. J. Brown, N. A. Gow, Antifungal agents: Mechanisms of action. Trends Microbiol. 11, 272-279 (2003).
75. J. R. Rees, R. W. Pinner, R. A. Hajjeh, M. E. Brandt, A. L. Reingold, The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance. Clin. Infect. Dis. 27, 1138-1147 (1998).
76. B. Spellberg, J. Edwards Jr., A. Ibrahim, Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18, 556-569 (2005).
77. Blastomycosis: http://www.rightdiagnosis.com/b/blastomycosis/prevalence. htm
78. K. C. Meyer, E. J. McManus, D. G. Maki, Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N. Engl. J. Med. 329, 1231-1236 (1993).
79. P. G. Pappas, J. C. Pottage, W. G. Powderly, V. J. Fraser, C.W. Stratton, S. McKenzie, M. L. Tapper, H. Chmel, F. C. Bonebrake, R. Blum, R. W. Shafer, C. King, W. E. Dismukes, Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann. Intern. Med. 116, 847-853 (1992).
80. P. G. Pappas, M. G. Threlkeld, G. D. Bedsole, K. O. Cleveland, M. S. Gelfand, W. E. Dismukes, Blastomycosis in immunocompromised patients. Medicine 72, 311-325 (1993).
81. Coccidioidomycosis: http://emedicine.medscape.com/article/215978- overview#a0156
82. M. Kleiman, in Principles and Practices of Pediatric Infectious Disease, S. S. Long, L. K. Pickering, C. G. Prober, Eds. (Churchill Livingstone, New York, 2008), pp. 1213-1217.
83. M. V. Cano, R. A. Hajjeh, The epidemiology of histoplasmosis: A review. Semin. Respir. Infect. 16, 109-118 (2001).
84. C. A. Kauffman, Histoplasmosis: A clinical and laboratory update. Clin. Microbiol. Rev. 20, 115-132 (2007).
85. R. Martinez, Paracoccidioidomycosis: The dimension of the problem of a neglected disease. Rev. Soc. Bras. Med. Trop. 43, 480 (2010).
86. K. H. Wong, S. S. Lee, K. C. Chan, T. Choi, Redefining AIDS: Case exemplified by Penicillium marneffei infection in HIV-infected people in Hong Kong. Int. J. STD AIDS 9, 555-556 (1998).
87. F. B. Yap, S. Thevarajah, J. Asmah, Penicillium marneffei infection in an African man. Dermatol. Online J. 16, 2 (2010).
88. T. C. Wu, J. W. Chan, C. K. Ng, D. N. Tsang, M. P. Lee, P. C. Li, Clinical presentations and outcomes of Penicillium marneffei infections: A series from 1994 to 2004. Hong Kong Med. J. 14, 103-109 (2008).